

Position Statement on Screening Mammography

ASBrS Breast Cancer Screening Guidelines Recommendations

1. Women age >25 should undergo formal risk assessment for breast cancer.
2. Women with an average risk of breast cancer should initiate yearly screening mammography at age 40.
3. Women with a higher-than-average risk of breast cancer should undergo yearly screening mammography and be offered yearly supplemental imaging: this screening should be initiated at a risk-based age.
4. Screening mammography should cease when life expectancy is <10 years.

Table 1 - Summary of ASBrS Recommendations for Breast Cancer Screening*

Women with average risk	• Women with non-dense breasts (A and B density)*	Annual mammography (3D preferred modality) starting at age 40, no need for supplemental imaging
	• Women with increased breast density (C and D density)*	Annual mammography (3D preferred modality) starting at age 40, and consider supplemental imaging
Women with higher-than-average risk	• Hereditary susceptibility from pathogenic mutation carrier status • Prior chest wall radiation age 10-30	Annual MRI starting at age 25, Annual mammography (3D preferred modality) starting at age 30
	• Predicted lifetime risk >20% by any model • Strong family history	Annual mammography (3D preferred modality) and access to supplemental imaging (MRI preferred modality) starting at age 35 when recommended by their physician
Women with prior history of breast cancer age ≥ 50 with non-dense breasts [#]		Annual mammography (3D preferred modality)
Women with prior history of breast cancer age < 50, or with dense breasts [#]		Annual mammography (3D preferred modality) and access to annual supplemental imaging (MRI preferred modality) when recommended by their physician

*All women to undergo risk assessment at age 25-30 and updated at appropriate intervals

[^]Class A or 1 density = fatty; Class B or 2 density = scattered fibroglandular density; Class C or 3 density = heterogeneously dense; Class D or 4 density = extremely dense

[#]Women with prior breast cancer who did not undergo bilateral mastectomy